🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mario A. Eisenberger

Johns Hopkins University

ORCID: 0000-0002-8787-3271

Also affiliated with Sidney Kimmel Cancer Center, Sidney Kimmel Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyNursing

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial”.

Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial

The Prostate(2021)10.1002/pros.24110

N/A

1.7DataRank · unranked

71 citations

Karim Boudadi, Wei Fu, Hao Wang, Rana Sullivan, Alice Jordan +12 more

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Nature Communications(2024)10.1038/s41467-023-44514-2

N/A

1.3DataRank · unranked

49 citations

Mary‐Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi +15 more

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy

European Journal of Cancer(2020)10.1016/j.ejca.2020.11.043

N/A

1.2DataRank · unranked

47 citations

Hao Wang, Su J. Lim ScM, Irina Rifkind, Nduku Ngomba, John T. Isaacs +10 more

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer(2020)10.1186/s12885-020-07000-2

N/A

1.1DataRank · unranked

32 citations

Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan +26 more

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0225

N/A

0.554DataRank · unranked

18 citations

Marianna Zahurak, Adel Mandl, Nicole A. Metri, Aliya Lalji, Elisabeth I. Heath +18 more

Test–retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer

The Prostate(2023)10.1002/pros.24577

N/A

0.263DataRank · unranked

4 citations

Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K. Buck +12 more

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5087

N/A

0DataRank · unranked

4 citations

Benjamin A. Teply, Su Jin Lim, Hao Wang, Shifeng Mao, William Kevin Kelly +10 more

1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2781

N/A

0DataRank · unranked

0 citations

M.L. Zahurek, Adel Mandl, Michelle A. Rudek, Elisabeth I. Heath, Catherine H. Marshall +13 more

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Annals of Oncology(2025)10.1016/j.annonc.2025.08.004

N/A

0DataRank · unranked

7 citations

Y. Chen, David F. Jarrard, Jorge A. García, R. Dreicer, Guoqiang Liu +12 more

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

The Prostate(2020)10.1002/pros.23955

N/A

0DataRank · unranked

37 citations

Eugene Shenderov, Mario A. Eisenberger, Sushant K. Kachhap, Drew M. Pardoll, Samuel R. Denmeade +2 more

Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate

Human Pathology(2020)10.1016/j.humpath.2020.04.014

N/A

0DataRank · unranked

7 citations

Michael C. Haffner, Mindy K. Graham, David Lim, Christine Davis, Eva Corey +7 more

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.116

N/A

0DataRank · unranked

2 citations

Ryan Phillips, William T. Shi, Su Jin Lim, Emmanuel S. Antonarakis, Steven P. Rowe +15 more

RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5576

N/A

0DataRank · unranked

1 citations

Hao Wang, Michael T. Schweizer, Michael A. Carducci, Channing J. Paller, Benjamin A. Teply +5 more

Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F‐DCFPyL test–retest cohort

The Prostate(2023)10.1002/pros.24483

N/A

0DataRank · unranked

14 citations

Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Alekandser Kosmala, Markus Essler +14 more